Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 5,425 GBp
Change Today +115.00 / 2.17%
Volume 1.3M
SHP On Other Exchanges
SHP is not on other exchanges.
As of 12:35 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

5,340 GBp
Previous Close
5,310 GBp
Day High
5,445 GBp
Day Low
5,330 GBp
52 Week High
03/20/15 - 5,745 GBp
52 Week Low
04/14/14 - 2,827 GBp
Market Cap
Average Volume 10 Days
5.60 GBp
Shares Outstanding
14.75 GBp
Dividend Yield
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHP) Key Developments

Shire Reportedly Looking To Buy BioMarin Pharma

There are market speculations that Shire plc (LSE:SHP) is considering acquiring BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) in a $65 billion deal. The shares of Shire rose today because of the merger speculations and UBS AG's confidence in Shire.

Shire plc and Cincinnati Children's Hospital Medical Center Announce Three-Year, Broad Research Collaboration for Rare Diseases

Shire plc and Cincinnati Children's Hospital Medical Center announced a three-year, broad research collaboration for rare diseases. The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research expertise. Cincinnati Children's has expertise in many fields of research that align with Shire's therapeutic areas of focus including, rare diseases, gastroenterology, nephrology and neurology. The partnership underscores Shire's long-term commitment to bringing innovative therapies to patients living with rare diseases around the world. Under the terms of the agreement, Shire will make an initial upfront payment to Cincinnati Children's and will have the opportunity to fund and offer scientific support to selected research programs. The emphasis will be on opportunities that have the potential to deliver a development candidate in less than three years from project initiation. Following the completion of each program, Shire will have an exclusive option to enter into a licensing agreement. Shire will be responsible for any further development and commercialization of development candidates arising from the collaboration. The agreement, negotiated by Shire and Cincinnati Children's Center for Technology Commercialization, represents a flexible model of collaboration between industry and academia.

Shire plc Announces Availability of New Titration Strength of ADHD Drug

Shire plc has announced the availability of Vyvanse 10mg capsules indicated for the treatment of attention-deficit/hyperactivity disorder, or ADHD. This new titration dose, which was approved by the FDA on October 30, 2014, is the seventh Vyvanse dosage strength available in addition to the 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg capsule strengths. In July 2014, Shire received approval for two additional administration options for Vyvanse capsules. In addition to swallowing whole or mixing the capsule contents with water, the contents can be mixed with yogurt or orange juice for patients who have trouble swallowing capsules.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 5,425.00 GBp +115.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$91.85 AUD +0.15
Eisai Co Ltd ¥8,803 JPY -115.00
Hospira Inc $87.88 USD +0.03
Mylan NV $61.63 USD -0.25
UCB SA €68.49 EUR +0.87
View Industry Companies

Industry Analysis


Industry Average

Valuation SHP Industry Range
Price/Earnings 14.5x
Price/Sales 7.9x
Price/Book 5.5x
Price/Cash Flow 14.0x
TEV/Sales 7.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at